Jeff Liter

Company: Luminary Therapeutics

Job title: President & Chief Executive Officer

Seminars:

Why a BAFF CAR for Autoimmune Versus CD19 Targeting? 4:30 pm

Developing a unique ligand-based CAR that targets three antigen receptors provides promising therapies for both oncology and autoimmune indications Utilizing the BAFF CAR to identify and remove autoreactive B-cells by directly targeting the B-cell activating factor receptors, eliminating the cause of inflammation at the sourceRead more

day: Conference Day One